Linked Data API

Show Search Form

Search Results

1695957
star this property registered interest false more like this
star this property date less than 2024-03-13more like thismore than 2024-03-13
star this property answering body
Northern Ireland Office more like this
star this property answering dept id 21 more like this
unstar this property answering dept short name Northern Ireland more like this
star this property answering dept sort name Northern Ireland more like this
star this property hansard heading Northern Ireland Protocol more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, further to the Written Answer by Lord Caine on 12 March (HL3032), to specify all the changes made to the protocol by the Windsor Framework; and whether Article 6 of the Acts of Union is affected by the protocol or the Windsor Framework. more like this
star this property tabling member printed
Baroness Hoey more like this
star this property uin HL3242 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-18more like thismore than 2024-03-18
star this property answer text <p>The Government’s position on the Windsor Framework, and its interaction with Article 6 of the Acts of Union, is set out in full in the Command Papers of 27 February 2023 and 31 January 2024.</p><p> </p> more like this
star this property answering member printed Lord Caine more like this
star this property question first answered
less than 2024-03-18T15:59:26.397Zmore like thismore than 2024-03-18T15:59:26.397Z
star this property answering member
4581
star this property label Biography information for Lord Caine more like this
star this property tabling member
210
star this property label Biography information for Baroness Hoey more like this
1694812
star this property registered interest false more like this
star this property date less than 2024-03-08more like thismore than 2024-03-08
star this property answering body
Department for Transport more like this
star this property answering dept id 27 more like this
unstar this property answering dept short name Transport more like this
star this property answering dept sort name Transport more like this
star this property hansard heading Road Safety Investigation Branch more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, further to (1) their announcement on 29 June 2022 about the creation of the Road Safety Investigation Branch, and (2) the Written Answer by Lord Davies of Gower on 7 March (HL2831), whether they will now answer the question put; namely, what progress they have made in setting up the Road Safety Investigation Branch. more like this
star this property tabling member printed
Lord Berkeley more like this
star this property uin HL3142 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-14more like thismore than 2024-03-14
star this property answer text <p>The Government is using the Automated Vehicles Bill to enable the creation of a capability within my department to investigate safety incidents involving at least one self-driving vehicle. Further development of this will be dependent on the availability of legislative time in future parliaments.</p><p> </p> more like this
star this property answering member printed Lord Davies of Gower more like this
star this property question first answered
less than 2024-03-14T12:45:32.827Zmore like thismore than 2024-03-14T12:45:32.827Z
star this property answering member
4499
star this property label Biography information for Lord Davies of Gower more like this
star this property tabling member
3526
star this property label Biography information for Lord Berkeley more like this
1694826
star this property registered interest false more like this
star this property date less than 2024-03-08more like thismore than 2024-03-08
star this property answering body
Department for Education more like this
star this property answering dept id 60 more like this
unstar this property answering dept short name Education more like this
star this property answering dept sort name Education more like this
star this property hansard heading Universities: Antisemitism more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government what steps they are taking to support Jewish university students following recent increases in incidents of antisemitism on campuses. more like this
star this property tabling member printed
The Marquess of Lothian more like this
star this property uin HL3156 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-15more like thismore than 2024-03-15
star this property answer text <p>Antisemitism, intimidation, and threats of violence must never be tolerated on university campuses. The Community Security Trust 2023 annual report highlights the unprecedented increase in antisemitic incidents in higher education (HE) and this unacceptable rise is deeply concerning. All antisemitism is abhorrent and universities should have robust systems to deal with incidents of support for unlawful antisemitic abuse and harassment. We will not tolerate unlawful harassment or the glorification of terrorism.</p><p>Since the 7 October attacks, we have actively intervened to ensure that universities act swiftly and appropriately to deal with incidents of antisemitism.</p><p>The Secretary of State for Education and the Minister for Skills wrote to all universities on 11 October 2023, urging them to respond swiftly to hate-related incidents, and actively reassure Jewish students that they can study without fear of harassment or intimidation. The Minister wrote again to Vice Chancellors on 16 November 2023, emphasising that they must use disciplinary measures wherever appropriate, highlighting the importance of police engagement, and reiterating that student visas could be suspended where a foreign national is found to have committed or incited acts of racial hatred. This was one of the key actions set out in the five point plan for tackling antisemitism in HE, which was published on 5 November 2023. The plan also involves:</p><ul><li>Calling for visas to be withdrawn from international students who incite racial hatred. Visas are a privilege, not a right, and we will not hesitate to remove them from people who abuse them.</li><li>Logging specific cases and sharing them with the Office for Students for their consideration.</li><li>Continuing to make it clear in all discussions that acts that may be criminal should be referred to the police.</li><li>Establishing a Tackling Antisemitism Quality Seal which will be an award available to universities who can demonstrate the highest standards in tackling antisemitism.</li></ul><p> </p><p>On 22 November 2023, the department announced in the Autumn Statement an additional £7 million over three years to tackle antisemitism in education. The Quality Seal will be the cornerstone of this package for universities, providing a framework of measures that will make clear what good practice is in tackling antisemitism in HE, and making sure that our universities are a safe and welcoming space for Jewish students and staff.</p><p>The department will not hesitate to take further action across education to stamp out antisemitism and harassment of Jewish pupils, students and staff.</p>
star this property answering member printed Baroness Barran more like this
star this property question first answered
less than 2024-03-15T14:38:42.787Zmore like thismore than 2024-03-15T14:38:42.787Z
star this property answering member
4703
star this property label Biography information for Baroness Barran more like this
star this property tabling member
259
star this property label Biography information for The Marquess of Lothian more like this
1694701
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Northern Ireland Office more like this
star this property answering dept id 21 more like this
unstar this property answering dept short name Northern Ireland more like this
star this property answering dept sort name Northern Ireland more like this
star this property hansard heading Public Expenditure and Taxation: Northern Ireland more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government what local revenue raising conditions were attached to the recent financial package awarded to the Northern Ireland Executive. more like this
star this property tabling member printed
Lord Empey more like this
star this property uin HL3112 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-15more like thismore than 2024-03-15
star this property answer text <p>The UK Government remains determined to support the Executive to maximise the opportunities presented by the financial package.</p><p> </p><p>To help stabilise the Executive’s financial position, the UK Government has agreed to pause its debt repayments from 2022-23 and 2023-24 of up to £559 million and will no longer require these funds to be repaid, subject to the Executive publishing a plan, which outlines how it will deliver sustainable public finances and services, and demonstrating implementation of that plan by May 2025.</p><p> </p><p>This sustainability plan must include the delivery of a balanced budget for 2024-25 by raising a minimum of £113 million through locally generated income. It will be for the Executive to determine if it will consider a different course of action to deliver the public services that Northern Ireland needs as part of its plan for financial sustainability.</p> more like this
star this property answering member printed Lord Caine more like this
star this property question first answered
less than 2024-03-15T14:15:42.547Zmore like thismore than 2024-03-15T14:15:42.547Z
star this property answering member
4581
star this property label Biography information for Lord Caine more like this
star this property tabling member
4216
star this property label Biography information for Lord Empey more like this
1694702
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Montelukast: Side Effects more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government what assessment they have made of any dangers to some users of the commonly prescribed asthma drug montelukast. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3113 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-18more like thismore than 2024-03-18
star this property answer text <p>Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.</p><p>Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.</p><p>Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.</p><p>As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.</p><p>We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL3114 more like this
HL3115 more like this
star this property question first answered
less than 2024-03-18T12:40:21.533Zmore like thismore than 2024-03-18T12:40:21.533Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath more like this
1694703
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Montelukast: Side Effects more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, in relation to the use of montelukast in the UK, what assessment they have made of the US Food and Drug Administration's issuing a “black box warning” in March 2020 about serious mental health side effects of the drug and restricting its use for allergic rhinitis. more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3114 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-18more like thismore than 2024-03-18
star this property answer text <p>Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.</p><p>Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.</p><p>Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.</p><p>As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.</p><p>We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL3113 more like this
HL3115 more like this
star this property question first answered
less than 2024-03-18T12:40:21.603Zmore like thismore than 2024-03-18T12:40:21.603Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath more like this
1694704
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Montelukast: Side Effects more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government what assessment they have made of the level of awareness by doctors of any dangers of the commonly prescribed drug montelukast, as highlighted by the US Food and Drug Administration in March 2020, that the use of the drug resulted in “a wide variety of mental health side effects have been reported, including completed suicides". more like this
star this property tabling member printed
Lord Hunt of Kings Heath more like this
star this property uin HL3115 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-18more like thismore than 2024-03-18
star this property answer text <p>Montelukast remains a safe and effective medicine in the treatment of asthma. Montelukast is indicated for use in the United Kingdom as an add on treatment for asthma patients who are inadequately controlled on inhaled corticosteroid treatment, and can be prescribed for the symptomatic relief of seasonal allergic rhinitis in patients with asthma. There is no licensed indication in the UK for the treatment of allergic rhinitis alone.</p><p>Neuropsychiatric effects such as depression have been included in the UK product information for montelukast since 2007. This has been subsequently updated with additional terms based on emerging evidence. This includes the most recent update in 2019, which more fully described the neuropsychiatric effects. In order to remind prescribers of the risk of neuropsychiatric effects with montelukast, a Drug Safety Update article was published by the Medicines and Healthcare products Regulatory Agency (MHRA) in 2019, to accompany the updated warnings.</p><p>Following a growing number of Yellow Card reports and queries from patients and caregivers, raising concerns about a potential ongoing lack of awareness of the risk of the neuropsychiatric effects with montelukast, the MHRA is conducting a further review of the current data.</p><p>As part of our review, we are evaluating all available evidence, including Yellow Card reports and queries received by the MHRA, literature publications, international regulatory changes, including those made by the United States’ Food and Drug Administration, and are listening to and learning from patients’ experiences. The MHRA has sought advice from our independent expert groups including paediatricians, specialists in mental and respiratory health, as well as experts in medicines safety.</p><p>We are considering all relevant regulatory actions that would provide the most effective way of increasing awareness to healthcare professionals, patients, and their caregivers. The MHRA is finalising the review process and will communicate on any further measures to minimise the risk, upon completion of our review.</p>
star this property answering member printed Lord Markham more like this
star this property grouped question UIN
HL3113 more like this
HL3114 more like this
star this property question first answered
less than 2024-03-18T12:40:21.637Zmore like thismore than 2024-03-18T12:40:21.637Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
2024
star this property label Biography information for Lord Hunt of Kings Heath more like this
1694706
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Breast Cancer: Screening more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, further to the Written Answer by Lord Markham on 1 February (HL1933), what are the agreed efficiency standards following restoration of breast screening services since the COVID-19 pandemic; how this decision was made; and by whom. more like this
star this property tabling member printed
Baroness Merron more like this
star this property uin HL3117 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-13more like thismore than 2024-03-13
star this property answer text <p>The standards for breast screening include an acceptable uptake and coverage level of greater than or equal to 70%, and an achievable uptake and coverage level of greater than or equal to 80%. Full details about the changes to breast screening standards before and after COVID-19, are available on the GOV.UK website, in an online only format.</p> more like this
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL3118 more like this
star this property question first answered
less than 2024-03-13T14:08:46.66Zmore like thismore than 2024-03-13T14:08:46.66Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
347
star this property label Biography information for Baroness Merron more like this
1694707
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Breast Cancer: Screening more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, further to the Written Answer by Lord Markham on 1 February (HL1933), what were the agreed efficiency standards for breast cancer screening prior to the restoration of services since the COVID-19 pandemic; and what are the agreed efficiency standards now. more like this
star this property tabling member printed
Baroness Merron more like this
star this property uin HL3118 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-13more like thismore than 2024-03-13
star this property answer text <p>The standards for breast screening include an acceptable uptake and coverage level of greater than or equal to 70%, and an achievable uptake and coverage level of greater than or equal to 80%. Full details about the changes to breast screening standards before and after COVID-19, are available on the GOV.UK website, in an online only format.</p> more like this
star this property answering member printed Lord Markham more like this
star this property grouped question UIN HL3117 more like this
star this property question first answered
less than 2024-03-13T14:08:46.723Zmore like thismore than 2024-03-13T14:08:46.723Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
347
star this property label Biography information for Baroness Merron more like this
1694708
star this property registered interest false more like this
star this property date less than 2024-03-07more like thismore than 2024-03-07
star this property answering body
Department of Health and Social Care more like this
star this property answering dept id 17 more like this
unstar this property answering dept short name Health and Social Care more like this
star this property answering dept sort name Health and Social Care more like this
star this property hansard heading Breast Cancer: Screening more like this
unstar this property house id 2 more like this
star this property legislature
25277
star this property pref label House of Lords remove filter
star this property question text To ask His Majesty's Government, further to the Written Answer by Lord Markham on 1 February (HL1933), what progress they have made on reducing variation in breast screening services since 2019. more like this
star this property tabling member printed
Baroness Merron more like this
star this property uin HL3119 more like this
star this property answer
answer
unstar this property is ministerial correction false more like this
star this property date of answer less than 2024-03-18more like thismore than 2024-03-18
star this property answer text <p>The NHS Breast Screening Programmes were affected by the COVID-19 pandemic, and some breast screening offices took the decision to pause services temporarily to support the pandemic response. All breast cancer screening services have now recovered from the pandemic, and have no backlog of people waiting to be screened.</p><p>Increasing uptake and reducing health inequalities remains paramount as part of the ambitions set out in the NHS Long Term Plan to directly support early detection and diagnosis of breast cancer. Regional commissioners are working closely with cancer alliances and cancer charities to develop uptake plans which address their specific populations needs.</p> more like this
star this property answering member printed Lord Markham more like this
star this property question first answered
less than 2024-03-18T12:38:55.117Zmore like thismore than 2024-03-18T12:38:55.117Z
star this property answering member
4948
star this property label Biography information for Lord Markham more like this
star this property tabling member
347
star this property label Biography information for Baroness Merron more like this